Floatz logo

Autologous Dendritic Cell-Tumor Cell Immunotherapy

Vaccination

Children's Cancer Group, ChinaCell therapyN/ADormant
D
29/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
14/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Vaccination cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

Autologous Dendritic Cell-Tumor Cell Immunotherapy is also rated in:

Metastatic MelanomaDormant
CCC
Indicative ·
48 / 100
View asset →
metastatic melanomaDormant
CC
Indicative ·
47 / 100
View asset →
melanomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →